Sondhi S, Castellano JM, Chong VZ, Rogoza RM, Skoblenick KJ, Dyck BA, Gabriele J, Thomas N, Ki K, Pristupa ZB, et al
1: BPC-157 Proposed use: Ulcerative colitis Proposed forms: Oral capsules, nasal spray, injections, transdermal cream, rectal suppository No
10 mg vial (common for starting doses) This is often the first vial new users receive
It immediately increased to a higher level until 4 h pi and then decreased to a minimum at 12 h pi , before slowly recovering
Patients should understand that while compounded semaglutide contains the same active pharmaceutical ingredient as branded GLP-1s, compounded formulations are not FDA-approved as single products
Lu proposes in [12] that the high glutathione concentration in hepatocytes is a storage mechanism for cysteine